-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Kieren Egan, & Malcolm Macleod
Clinical Trail Methodology: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomes: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The future of TB treatment: trial shows potential for a new TB drug
News and Views: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation